Attorney General Ellison reaches another settlement with generic-drug manufacturer for illegal behavior

Glenmark to pay almost $30M nationally, including $187K to Minnesota — brings total AG Ellison recovered for Minnesota from lawsuits against generics manufacturers to $567K

Latest settlement in three multistate lawsuits against generics manufacturers, called ‘largest cartel in the history of the United States’

Consumers also eligible for restitution if they purchased generic prescription drugs from 2009–19

July 17, 2026 (SAINT PAUL) — Minnesota Attorney General Keith Ellison announced today he has joined a coalition of 48 states and territories in reaching a $29.6 million nationwide settlement with Glenmark to resolve allegations that the generic-drug manufacturer engaged in a widespread, long-running conspiracy to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade with regard to numerous generic prescription drugs. As part of the settlement agreement, Glenmark will cooperate in three ongoing multistate lawsuits against 33 corporate defendants and 25 individual executives in which Minnesota is a plaintiff. Glenmark has further agreed to make a series of internal reforms that will ensure fair competition and its compliance with antitrust laws.

Minnesota’s share of today’s settlement with Glenmark that Attorney General Ellison recovered is more than $187,000. The settlement with Glenmark follows prior settlements with generic-drug manufacturers Lannett, Bausch, Apotex, and Heritage: all together, the national value of those settlements is more than $97 million, with Attorney General Ellison having recovered more than $567,000 for Minnesota. The settlements come in a series of antitrust cases against companies and individuals in the generic-drug industry in which Minnesota is a plaintiff as part of a coalition of nearly all states and territories, led by Connecticut Attorney General William Tong. The behavior of the defendant companies and individuals has been called “most likely the largest cartel in the history of the United States.”

Consumers who purchased a generic prescription drug manufactured by Glenmark, Lannett, Bausch, Apotex, or Heritage between May 2009 and December 2019 may also be eligible for compensation. Consumers should call (866) 290-0182, email info@AGGenericDrugs.com, or visit www.AGGenericDrugs.com to determine their eligibility.

“This settlement illustrates again that one of the biggest drivers making it tough for Minnesotans to afford their lives is illegal corporate behavior that drives drug prices artificially high and keeps them there,” Attorney General Ellison said. “Generic drugs are supposed to save consumers money and help them afford the medicine they need to live, but Glenmark and other generic-drug manufacturers have illegally conspired to keep drug prices high and profit off Minnesotans’ health. This coalition and I will not let up in our efforts to stop this illegal behavior and compensate the state and consumers.”

Minnesota’s three lawsuits against generics manufacturers for conspiracy to control prices, reduce competition, and restrain trade

The first complaint, which Minnesota and the coalition filed in 2016, includes Heritage and 17 other corporate defendants, two individual defendants, and 15 generic drugs. Two former executives from Heritage Pharmaceuticals, Jeffery Glazer and Jason Malek, have since entered into settlement agreements and are cooperating.

Minnesota and the coaliton filed the second complaint  in 2019 against Teva Pharmaceuticals and 21 of the nation’s largest generic drug manufacturers. The complaint names 16 individual senior executive defendants.

The third complaint, filed in 2020, focuses on 80 topical generic drugs that account for billions of dollars of sales in the United States and names 26 corporate defendants and 10 individual defendants. Seven additional pharmaceutical executives have been cooperating to support the States’ claims.

This lawsuit will be the first one to be tried in court, likely in late 2026 in Connecticut.

The cases all stem from a series of investigations built on evidence from several cooperating witnesses at the core of the different conspiracies, a massive document database of over 20 million documents, and a phone records database containing millions of call detail records and contact information for over 600 sales and pricing individuals in the generics industry. Each complaint addresses a different set of drugs and defendants and lays out an interconnected web of competing industry executives that met with each other during industry dinners, "girls nights out," lunches, cocktail parties, golf outings and communicated via frequent telephone calls, emails and text messages that sowed the seeds for their illegal agreements. Throughout the complaints, defendants use terms like "fair share," "playing nice in the sandbox," and "responsible competitor" to describe how they unlawfully discouraged competition, raised prices and enforced an ingrained culture of collusion.

Among the records the states obtained is a two-volume notebook containing the contemporaneous notes of one of the states’ cooperators that memorialized his discussions during phone calls with competitors and internal company meetings over a period of several years.

In addition to Minnesota, the states and territories settling with Glenmark today are Alaska, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Northern Mariana Islands, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, U.S. Virgin Islands, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.